The results indicated that CENPA was positively associated with most immune checkpoints in thyroid carcinoma (THCA), lung adenocarcinoma (LUAD), liver hepatocellular carcinoma (LIHC), lower-grade glioma (LGG), kidney renal clear cell carcinoma (KIRC), breast invasive carcinoma (BRCA), and bladder urothelial carcinoma (BLCA), while it showed a negative correlation with most immune checkpoints in thymoma (THYM), lung squamous cell carcinoma (LUSC), glioblastoma multiforme (GBM), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and adrenocortical carcinoma (ACC) (Fig 7B). This evidence concerns the gene CENPA and bladder transitional cell carcinoma.